TransMedics Group Inc. (TMDX) exhibits 59.9% gross margins and 18.1% return on invested capital within Health Care (Biotechnology: Electromedical & Electrotherapeutic Apparatus), balanced against a 14.6x enterprise multiple and 4.8% implied options volatility.
Sustained 59.9% gross profitability converts into 17.9% operating margin and 18.1% ROIC, outpacing sector cost of capital.
ROIC: 18.1% // GM: 59.9%YoY revenue trajectory of +37.1% paired with 5.74% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +37.1% // FCF YLD: 5.74%Altman Z-Score of 3.50 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 3.50 // F-SCORE: 8/9Trading at 12.2x trailing P/E (10.2x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 12.2x // EV/EBITDA: 14.6xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $67.12 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Electromedical & Electrotherapeutic Apparatus require continuous execution to defend 31.4% net margins.
NET MARGIN: 31.4% // D/E: 0.45x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for TMDX & activate live FRED threshold breach alerts.